fingolimod (FTY720)

DRUG3 trials

Sponsors

Novartis, Novartis Pharmaceuticals, University Hospital, Basel, Switzerland

Conditions

Relapsing Remitting Multiple SclerosisRenal InsufficiencyRett's Syndrome

Phase 1

Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.

CompletedNCT00731523

NovartisRenal Insufficiency

Start: 2008-07-31Updated: 2020-12-09

Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome

CompletedNCT02061137

University Hospital, Basel, SwitzerlandRett's Syndrome

Start: 2013-08-31End: 2018-04-30Updated: 2018-06-15

Phase 4

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

CompletedNCT01498887

Novartis PharmaceuticalsRelapsing Remitting Multiple Sclerosis

Start: 2011-12-24End: 2015-12-26Updated: 2019-01-25

Related Papers

Fingolimod in children with Rett syndrome: the FINGORETT study

Orphanet Journal of Rare Diseases2021-01-0624 citations